Boston Scientific (BSX) Q3 Sales $5.14B; Cuts FY26 Outlook
Boston Scientific reported Q3 2026 net sales of $5.138B, GAAP EPS of $0.40, and adjusted EPS of $0.73. The company reduced its FY26 outlook, expecting sales growth of ~4.25% and adjusted EPS of $3.16–$3.18. Q4 sales are anticipated to decline by ~1% to 3%, with adjusted EPS of $0.77–$0.79.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered outlook are likely to trigger a sell‑off in the short term, though long‑term fundamentals remain intact.
Market read
First‑report earnings and guidance cut for a large‑cap med‑tech firm; high relevance for traders.
What to watch
The company’s pipeline and upcoming product launches could offset short‑term sales slowdown.
Background
Boston Scientific disclosed its Q3 2026 results and revised FY26 guidance amid a recent cybersecurity incident.
Ticker impact
Boston Scientific reported Q3 2026 net sales of $5.138B and cut FY26 sales growth guidance to ~4.25% (3.75% organic).
likely downward pressure as investors price in weaker sales growth and lower EPS guidance
The earnings release contains fresh, material numbers and a downward revision of FY26 outlook, which is a primary catalyst for short‑term price movement.
Market effects
May weigh on the broader medical device sector as peers face similar growth concerns.
Potentially modest impact on US healthcare indices.
Limited to investors tracking US‑listed med‑tech stocks.
Counterpoint
If the cybersecurity disruption is resolved quickly, the guidance cut could be temporary and the stock may rebound.
Key entities
- CompanyBoston Scientific
US‑listed medical device manufacturer (ticker BSX).
